Swiss lawmakers reject medicines initiative but back government alternative

The National Council has rejected the popular initiative on medicine security and backed a narrower government plan. The decision on September 24, 2026 keeps the issue of medicine shortages firmly on Switzerland’s political agenda, while shifting the legislative route toward the Federal Council’s direct counter-proposal.

The initiative, titled “Yes to the security of medical supplies”, sought action across the full pharmaceutical chain. Its supporters wanted Switzerland to strengthen research, development, production and storage of medicines. The National Council considered the problem genuine, according to the parliamentary account reported by Swissinfo, but judged the initiative too broadly worded and too far-reaching.

The vote does not end the parliamentary process. The Council of States must still examine both the initiative and the counter-proposal. Until then, the National Council’s position provides the clearest indication of where the larger chamber sees room for federal action: stronger oversight and targeted measures, with fewer broad obligations written directly into the constitutional framework.

The dispute comes after repeated concerns over medicine availability in Switzerland and wider disruption risks affecting international supply chains.

The government’s counter-proposal would give the Confederation a central role in tracking shortages before they become acute. Under the planned framework, federal authorities would monitor the medicine supply situation centrally and proactively. They would also gain powers to take measures designed to prevent or remedy disruptions.

That approach would move Switzerland toward a more coordinated system. Responsibility for identifying risks would sit more clearly at federal level, allowing authorities to gather information, assess vulnerabilities and respond when supplies begin to tighten. The proposal also points to intervention tools beyond emergency communication, including economic incentives and direct procurement.

The government plan would allow the Confederation to manufacture medical supplies domestically or arrange for their production. It would also strengthen international cooperation, reflecting the fact that Swiss patients and pharmacies depend heavily on cross-border production networks, imported ingredients and global logistics.

The source material does not specify the size of the proposed incentives, the medicines that would receive priority or the federal body that would lead the monitoring system. Those details will matter as Parliament turns the broad policy direction into legislation. The Council of States will have an early opportunity to test the plan’s scope and financing.

The initiative was submitted in 2024 by 20 organisations and companies from Switzerland’s healthcare sector. Supporters said hundreds of medicines were already in short supply, giving the campaign a direct connection to the experience of pharmacies, healthcare providers and patients.

Their proposal covered the entire value chain. It called for more Swiss capacity in research and development, domestic manufacturing and the storage of medicines. The breadth reflected a concern that shortages cannot be managed only when a product disappears from pharmacy shelves. Production decisions, procurement practices, stockpiling and international dependencies all influence whether a medicine remains available.

National Council lawmakers accepted the underlying problem while rejecting the initiative’s wording and reach. That distinction now shapes the political debate. Supporters will have to assess whether the counter-proposal offers enough protection for essential medicines, while opponents of the initiative will need to show that a targeted framework can deliver results without imposing excessive costs or rigid requirements.

Swissinfo has also reported on lessons from the Covid period and risks linked to instability in the Middle East. Those developments have kept supply resilience in focus, even when immediate shortages are not expected.

The next test comes in the Council of States, which has not yet taken a position. Its review will determine whether the government’s counter-proposal advances with the same political direction or whether senators seek stronger obligations for production, procurement and reserves.

The unresolved debate has practical consequences for Swiss patients and healthcare providers. A federal monitoring system could improve visibility when supplies tighten. Incentives and public procurement could help authorities secure products that the market does not reliably provide. Domestic production could add resilience for selected medical supplies, although the source material does not identify which products would qualify or how such manufacturing would be funded.

International cooperation will remain part of the solution. Switzerland cannot isolate its medicine supply from global production networks, transport routes and foreign manufacturers. The government’s plan acknowledges that reality while adding federal tools for managing domestic risks.

Parliament must now define how quickly authorities should act, which medicines deserve priority and how the system should balance resilience against cost. The National Council has chosen a targeted legislative path. The Council of States will decide how far that path should go.